| Literature DB >> 36030231 |
Yajun Yao1, Xindi Li1, Yun Xu1, Xiaofang Liang2, Liu Yang2, Fu-Dong Shi1,3,4, Xinghu Zhang1, De-Cai Tian5, Xuxiang Zhang6.
Abstract
BACKGROUND: Antibodies against myelin-oligodendrocyte-glycoprotein (MOG-Abs) associated disease (MOGAD) has been recognized as a disease entity. Optic neuritis (ON) is the most common symptom in MOGAD. To demonstrate the differences in retinal microvascular characteristics between patients with MOGAD-ON and aquaporin-4 antibody (AQP4-Ab) positive ON.Entities:
Keywords: MOGAD; NMOSD; OCTA; Optic neuritis
Mesh:
Substances:
Year: 2022 PMID: 36030231 PMCID: PMC9419345 DOI: 10.1186/s12883-022-02848-2
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.903
The clinical characteristic of enrolled patients and health participants
| MOG-ON | AQP4-ON | HC | |
|---|---|---|---|
| Number of patients | 17 | 26 | 30 |
| Gender (Male / Female) | 8/9* | 2/24 | 9/21 |
| Age (years) | 34.88 (14.12) | 40.50 (11.99) | 38.62 (12.20) |
| ON history (unilateral / bilateral) | 8/9 | 12/14 | NA |
| Number of eyes | 26 | 40 | 60 |
| ON disease duration (mon, per eye) | 42.0 (6–156) | 54.0 (8–144) | NA |
| Number of ON episodes (n, per eye) | 1.35 (0.56) | 2.05 (1.84) | NA |
| Duration since last ON (mon, per eye) | 12 (6–156) | 24 (6–144) | NA |
| Visual accuracy (logMAR, per eye) | 0.33 (0.26)* | 0.66 (0.68) | NA |
| EDSS | 3.00 (1–6.5) | 3.5 (2–6.5) | NA |
AQP4 Aquaporin4-IgG seropositive, EDSS Expanded disability status scale, HC Health controls, MOGAD MOG-Ab-associated disease, ON Optical neuritis, NA Not applicable, * p<0.05
Retina structural data of MOGAD-ON eyes in comparison to AQP4-Ab-ON eyes and HC
| MOG-ON | AQP4-ON | HC | MOG-ON VS. AQP4-ON | MOG-ON VS. HC | |||||
|---|---|---|---|---|---|---|---|---|---|
| Eye = 26 | Eye = 40 | Eye = 60 | B | SE | p | B | SE | p | |
| pRNFL (um) | 75.49 (17.98) | 78.69 (18.59) | 119.74 (10.08) | −0.015 | 0.016 | 0.350 | −0.238 | 0.071 | 0.001* |
| TEM-RNFL (um) | 49.80 (16.90) | 55.37 (14.78) | 84.03 (9.38) | −0.020 | 0.019 | 0.310 | −0.163 | 0.039 | 0.000* |
| SUP-RNFL (um) | 92.84 (24.56) | 96.56 (29.42) | 146.31 (14.71) | −0.010 | 0.010 | 0.317 | −0.305 | 0.117 | 0.009* |
| NAS-RNFL (um) | 65.48 (14.25) | 64.88 (14.25) | 96.03 (15.68) | −0.003 | 0.019 | 0.857 | −0.134 | 0.031 | 0.000* |
| INF-RNFL (um) | 93.01 (28.18) | 97.79 (29.26) | 152.58 (17.51) | −0.008 | 0.010 | 0.392 | −0.103 | 0.025 | 0.000* |
| GCC (um) | 74.71 (10.19) | 74.28 (13.70) | 99.12 (5.07) | −0.013 | 0.022 | 0.555 | −0.029 | 0.018 | 0.000* |
| Outer Retina (um) | 172.21 (6.63) | 175.67 (8.82) | 175.62 (7.55) | −0.058 | 0.039 | 0.137 | −0.184 | 0.029 | 0.062 |
AQP4-ON Aquaporin4-IgG seropositive optical neuritis, B Beta, GCC Ganglion cell complex, also refer to the inner retina, HC Health controls, INF Inferior quadrant, MOGAD-ON MOG-Ab-associated disease optical neuritis, NAS Nasal quadrant, pRNFL peri-papillary retinal nerve fiber layer, SUP Superior quadrant, SE Standard error, TEM Temporal quadrant, * p<0.05
Retina angiography data of MOGAD-ON eyes in comparison to AQP4-Ab-ON eyes and health controls
| MOG-ON | AQP4-ON | HC | MOG-ON VS. AQP4-ON | MOG-ON VS. HC | |||||
|---|---|---|---|---|---|---|---|---|---|
| Eye = 26 | Eye = 40 | Eye = 60 | B | SE | p | B | SE | p | |
| Optic disk RPC (%) | 49.53 (4.87) | 49.14 (6.42) | 55.35 (3.82) | −0.072 | 0.051 | 0.154 | −0.288 | 0.069 | 0.000* |
| Capillary RPC (%) | 52.74 (5.98) | 48.63 (7.51) | 51.14 (2.13) | −0.058 | 0.046 | 0.203 | −0.808 | 0.194 | 0.000* |
| Superficial retina VD | |||||||||
| Whole VD (%) | 44.22 (4.69) | 46.01 (6.31) | 51.99 (2.88) | −0.041 | 0.041 | 0.320 | −0.560 | 0.122 | 0.000* |
| Fovea (%) | 13.16 (6.43) | 15.31 (6.02) | 19.91 (6.60) | −0.045 | 0.045 | 0.310 | −0.168 | 0.452 | 0.000* |
| para-TEM (%) | 46.13 (5.55) | 48.27 (6.56) | 53.31 (3.38) | −0.029 | 0.039 | 0.462 | −0.323 | 0.074 | 0.000* |
| para-SUP (%) | 47.93 (6.07) | 49.26 (6.77) | 54.53 (4.02) | −0.039 | 0.043 | 0.366 | −0.263 | 0.065 | 0.000* |
| para-NAS (%) | 44.64 (6.16) | 47.93 (6.57) | 52.83 (3.86) | −0.090 | 0.044 | 0.040* | −0.315 | 0.073 | 0.000* |
| para-INF (%) | 45.22 (6.73) | 47.87 (6.84) | 53.43 (4.76) | −0.066 | 0.042 | 0.110 | −0.231 | 0.054 | 0.000* |
| peri-TEM (%) | 42.54 (3.56) | 44.30 (5.56) | 48.40 (2.77) | −0.097 | 0.058 | 0.094 | −0.498 | 0.103 | 0.000* |
| peri-SUP (%) | 45.01 (5.18) | 46.54 (7.39) | 53.09 (2.98) | −0.043 | 0.428 | 0.313 | −0.511 | 0.116 | 0.000* |
| peri-NAS (%) | 46.73 (6.0)1 | 48.92 (6.83) | 55.89 (2.77) | −0.059 | 0.436 | 0.173 | −0.507 | 0.112 | 0.000* |
| peri-INF (%) | 44.41 (6.07) | 46.27 (7.34) | 52.53 (3.17) | −0.053 | 0.417 | 0.207 | −0.402 | 0.091 | 0.000* |
| Deep retina VD | |||||||||
| Whole VD (%) | 48.01 (7.58) | 52.61 (6.72) | 54.84 (5.41) | −0.091 | 0.040 | 0.022* | −0.163 | 0.045 | 0.000* |
| Fovea (%) | 29.28 (7.03) | 31.99 (6.88) | 37.12 (8.06) | −0.046 | 0.041 | 0.259 | −0.123 | 0.036 | 0.001* |
| para-TEM (%) | 54.38 (8.16) | 57.78 (4.84) | 59.57 (3.72) | −0.086 | 0.050 | 0.087 | −0.192 | 0.062 | 0.002* |
| para-SUP (%) | 53.75 (7.39) | 57.73 (5.19) | 58.25 (4.35) | −1.488 | 1.532 | 0.044* | −0.137 | 0.048 | 0.004* |
| para-NAS (%) | 53.75 (8.18) | 57.64 (5.69) | 59.47 (4.24) | −0.107 | 0.049 | 0.029* | −0.172 | 0.053 | 0.001* |
| para-INF (%) | 50.77 (8.44) | 56.03 (5.98) | 57.38 (5.32) | −0.101 | 0.042 | 0.016* | −0.142 | 0.042 | 0.001* |
| peri-TEM (%) | 51.52 (6.90) | 54.68 (6.76) | 57.86 (4.86) | −0.073 | 0.039 | 0.062 | −0.197 | 0.052 | 0.000* |
| peri-SUP (%) | 48.12 (9.65) | 53.18 (8.12) | 56.40 (6.65) | −0.063 | 0.032 | 0.052 | −0.129 | 0.038 | 0.001* |
| peri-NAS (%) | 47.18 (9.17) | 54.19 (7.45) | 55.01 (6.50) | −0.098 | 0.035 | 0.005* | −0.130 | 0.037 | 0.000* |
| peri-INF (%) | 47.58 (8.55) | 52.86 (8.09) | 55.21 (6.70) | −0.073 | 0.033 | 0.028* | −0.125 | 0.036 | 0.000* |
AQP4-ON Aquaporin4-IgG seropositive optical neuritis, B Beta, GCC Ganglion cell complex, HC Health controls, INF Inferior quadrant, MOGAD-ON MOG-Ab-associated disease optical neuritis, NAS Nasal quadrant, pRNFL peri-papillary retinal nerve fiber layer, RPC radial peripapillary capillaries, SUP Superior quadrant, SE Standard error, TEM Temporal quadrant, VD Vessel densities, * p<0.05
Fig. 1The proportion of eyes with reduced RNFL in each quadrant (MOGAD-ON and AQP4-ON). Compared with the manufacturer’s specification data, MOGAD-ON eyes with reduced thickness of RNFL in different quadrants accounted for 62–88%. AQP4-ON eyes with reduced thickness of RNFL in different quadrants accounted for 58–83%. The proportion of MOG-ON eyes had reduced RNFL thickness in the superior-temporal and temporal-superior regions, which were significantly higher than that of AQP4-ON eyes (58–63%, p = 0.004 in temporal-superior area, p = 0.001 in superior-temporal area). AQP4-ON: Aquaporin4-IgG seropositive optical neuritis, MOGAD-ON: MOG-Ab-associated disease optical neuritis, TS: temporal-superior quadrant; ST: superior-temporal quadrant; SN: superior-nasal quadrant; NS: nasal-superior quadrant; NS: nasal-superior quadrant; IN: inferior-nasal quadrant; NI: nasal-inferior quadrant; IT: inferior-temporal quadrant; TI: temporal-inferior quadrant
The correlation between OCT angiography parameters and OCT parameters in ON
| RNFL Average | Inner Retina (GCC) | Outer Retina | |||||||
|---|---|---|---|---|---|---|---|---|---|
| B | SE | p | B | SE | p | B | SE | p | |
| Whole VD (%) | 2.231 | 0.321 | 0.000* | 1.568 | 0.226 | 0.000* | −0.021 | 0.208 | 0.918 |
| Fovea (%) | 1.501 | 0.312 | 0.000* | 0.894 | 0.229 | 0.000* | −0.175 | 0.175 | 0.317 |
| para-TEM (%) | 1.683 | 0.326 | 0.000* | 1.082 | 0.231 | 0.000* | −0.033 | 0.181 | 0.856 |
| para-SUP (%) | 1.607 | 0.309 | 0.000* | 0.968 | 0.231 | 0.000* | −0.021 | 0.180 | 0.907 |
| para-NAS (%) | 1.572 | 0.318 | 0.000* | 0.891 | 0.239 | 0.000* | 0.067 | 0.186 | 0.719 |
| para-INF (%) | 1.528 | 0.295 | 0.000* | 1.204 | 0.197 | 0.000* | −0.042 | 0.173 | 0.810 |
| peri-TEM (%) | 2.360 | 0.388 | 0.000* | 1.675 | 0.271 | 0.000* | −0.049 | 0.2391 | 0.839 |
| peri-SUP (%) | 1.928 | 0.257 | 0.000* | 1.239 | 0.195 | 0.000* | 0.280 | 0.127 | 0.027* |
| peri-NAS (%) | 2.111 | 0.282 | 0.000* | 1.323 | 0.214 | 0.000* | 0.261 | 0.128 | 0.042* |
| peri-INF (%) | 1.687 | 0.265 | 0.000* | 1.282 | 0.173 | 0.000* | 0.020 | 0.166 | 0.904 |
| Whole VD (%) | 0.226 | 0.320 | 0.480 | 0.093 | 0.225 | 0.678 | 0.462 | 0.152 | 0.002* |
| Fovea (%) | 1.140 | 0.319 | 0.000* | 0.695 | 0.229 | 0.002* | −0.008 | 0.179 | 0.965 |
| para-TEM (%) | 0.347 | 0.407 | 0.394 | 0.053 | 0.284 | 0.851 | 0.458 | 0.177 | 0.010* |
| para-SUP (%) | 0.063 | 0.387 | 0.871 | −0.138 | 0.267 | 0.605 | 0.472 | 0.166 | 0.004* |
| para-NAS (%) | 0.242 | 0.349 | 0.488 | −0.089 | 0.242 | 0.713 | 0.459 | 0.157 | 0.003* |
| para-INF (%) | 0.048 | 0.319 | 0.881 | 0.008 | 0.223 | 0.970 | 0.440 | 0.145 | 0.002* |
| peri-TEM (%) | 0.422 | 0.331 | 0.202 | 0.230 | 0.232 | 0.320 | 0.380 | 0.156 | 0.015* |
| peri-SUP (%) | 0.197 | 0.564 | 0.453 | 0.021 | 0.185 | 0.910 | 0.3765 | 0.123 | 0.002* |
| peri-NAS (%) | 0.052 | 0.265 | 0.844 | −0.037 | 0.185 | 0.840 | 0.369 | 0.117 | 0.002* |
| peri-INF (%) | 0.271 | 0.265 | 0.306 | 0.259 | 0.183 | 0.157 | 0.365 | 0.132 | 0.006* |
B Beta, GCC Ganglion cell complex, INF Inferior quadrant, NAS Nasal quadrant, pRNFL peri-papillary retinal nerve fiber layer, SUP Superior quadrant, SE Standard error, TEM Temporal quadrant; VD: vessel densities, * p<0.05